Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00425139
Other study ID # HL-04-001
Secondary ID
Status Completed
Phase N/A
First received January 19, 2007
Last updated March 19, 2015
Start date October 2004
Est. completion date November 2005

Study information

Verified date January 2007
Source HopeLab Foundation
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effects of playing the interactive video game, Re-Mission, on patient outcomes, including adherence to medical treatment regimes, self-care behaviors, quality of life, stress, communication, control, and knowledge.


Description:

POPULATION: Approximately 340 patients will be enrolled in this study. Patients will be 13 to 29 years of age with any cancer (original diagnosis or relapse), currently receiving treatment and expected to be on treatment for at least 4 - 6 months following Baseline assessment, and able to communicate effectively in English, Spanish, or French. Approximately 170 patients will be enrolled in each of the two treatment groups. Each group will receive either the "Re-Mission" video game and a popular interactive video game, or just the popular interactive video game.

DESIGN: This is a multi-center, randomized trial, with patients randomized to one of two groups. One group (50% of patients) will receive the active intervention, which is the psycho-educational video game module called Re-Mission and a popular video game (hereafter "RE-MISSION") and another group (50 % of patients) will be in a game control group and receive a popular video game only (hereafter "GAME CONTROL. The games in the RE-MISSION and GAME CONTROL groups are delivered on identical mini, personal computers (hereafter "Mini-PC").

INTERVENTION: Each patient in the RE-MISSION group will be asked to play "Re-Mission" along with the popular video game for at least one hour a week for a period of ten to fourteen weeks. "Re-Mission" presents a 3-D environment in which the player can manipulate a humanoid character inside the virtual body of a patient with cancer. Game-play consists of guiding the character to destroy cancer cells and other "enemies" in the body (e.g., bacteria) while avoiding injury or weakness. During the process of playing the game and guiding the character through a series of missions, the player learns about chemotherapy and other medical treatments, health-promoting self-care behaviors, infections, and pain management. In addition, the game has also been designed to facilitate the patient's ability to share knowledge and concerns with others.

DURATION OF STUDY: 9 -12 months


Recruitment information / eligibility

Status Completed
Enrollment 375
Est. completion date November 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 13 Years to 29 Years
Eligibility Inclusion Criteria:

1. Male or female patient 13 to 29 years of age with a cancer diagnosis.

2. Patient who is currently receiving treatment and is expected to remain on treatment for at least 4 - 6 months.

Exclusion Criteria:

1. Patient who has a history of seizures due to photosensitivity.

2. Patient who has been determined by the investigator to be incapable of following the study schedule or study directions for any reason.

3. Patient who can not communicate effectively with study personnel in English, Spanish, or French.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Behavioral:
Re-Mission


Locations

Country Name City State
Australia Royal Children's Hospital Parkville Victoria
Canada Calgary Alberta Children's Hospital Calgary Alberta
Canada McMaster University Hamilton Ontario
Canada Hôpital Ste-Justine Montreal Quebec
Canada McGill Univ Health Ctr - Montreal Children's Hospital Montreal Quebec
Canada Children's Hospital of Eastern Ontario Ottawa Ontario
Canada Centre Hospitalier Universitaire de Québec Ste-Foy Quebec
United States Children's Hospital of New Mexico Albuquerque New Mexico
United States Children's Hospital of Austin Austin Texas
United States Dana-Farber Cancer Institute and Children's Hospital Boston Massachusetts
United States Driscoll Children's Hospital Corpus Christi Texas
United States City of Hope National Medical Center Duarte California
United States Children's Hospital of SW Florida / Lee Memorial Health System Fort Myers Florida
United States Cook Children's Medical Center Fort Worth Texas
United States DeVos Children's Hospital Grand Rapids Michigan
United States St John Van Elslander Cancer Center Grosse Pointe Woods Michigan
United States Kapiolani Medical Center Honolulu Hawaii
United States Nemours Children's Clinic-Jacksonville Jacksonville Florida
United States Children's Mercy Hospital Kansas City Missouri
United States Los Angeles Children's Center for Cancer and Blood Disease Los Angeles California
United States LSU Children's Hospital of New Orleans New Orleans Louisiana
United States Children's Hospital of the King's Daughters Norfolk Virginia
United States Children's Hospital of Orange County Orange California
United States Lucile Packard Children's Hospital at Stanford Palo Alto California
United States Doernbecher Childrens Hospital - OHSU Portland Oregon
United States Legacy Emanuel Children's Cancer Program Portland Oregon
United States Golisano Children's Hospital, University of Rochester Rochester New York
United States Christus Santa Rosa Children's Hospital San Antonio Texas
United States Deaconess Medical Center Spokane Washington
United States Washington University St. Louis Missouri
United States Children's Health Care - Minneapolis St. Paul Minnesota
United States All Children's Hospital St. Petersburg Florida
United States St. Joseph's Children's Hospital of Tampa Tampa Florida
United States Warren Clinic / Saint Francis Hospital Tulsa Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
HopeLab Foundation

Countries where clinical trial is conducted

United States,  Australia,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adherence
Primary Self-efficacy
Primary Quality of life
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab

External Links